TN2013000400A1 - Imidazopyridazines as akt kinase inhibitors - Google Patents
Imidazopyridazines as akt kinase inhibitorsInfo
- Publication number
- TN2013000400A1 TN2013000400A1 TNP2013000400A TN2013000400A TN2013000400A1 TN 2013000400 A1 TN2013000400 A1 TN 2013000400A1 TN P2013000400 A TNP2013000400 A TN P2013000400A TN 2013000400 A TN2013000400 A TN 2013000400A TN 2013000400 A1 TN2013000400 A1 TN 2013000400A1
- Authority
- TN
- Tunisia
- Prior art keywords
- imidazopyridazines
- kinase inhibitors
- akt kinase
- akt
- inhibitors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Abstract
Imidazopyridazines of formula (I) a process for their production and the use thereof.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161472732P | 2011-04-07 | 2011-04-07 | |
PCT/EP2012/056300 WO2012136776A1 (en) | 2011-04-07 | 2012-04-05 | Imidazopyridazines as akt kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
TN2013000400A1 true TN2013000400A1 (en) | 2015-03-30 |
Family
ID=45953129
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TNP2013000400A TN2013000400A1 (en) | 2011-04-07 | 2013-10-03 | Imidazopyridazines as akt kinase inhibitors |
Country Status (42)
Families Citing this family (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9029408B2 (en) | 2008-06-16 | 2015-05-12 | Gtx, Inc. | Compounds for treatment of cancer |
TR201903981T4 (en) | 2008-06-16 | 2019-04-22 | Univ Ohio State Res Found | Compounds for cancer treatment. |
US9447049B2 (en) | 2010-03-01 | 2016-09-20 | University Of Tennessee Research Foundation | Compounds for treatment of cancer |
EP2542081A4 (en) | 2010-03-01 | 2013-07-31 | Gtx Inc | Compounds for treatment of cancer |
US11084811B2 (en) | 2010-03-01 | 2021-08-10 | Oncternal Therapeutics, Inc. | Compounds for treatment of cancer |
RS54480B1 (en) * | 2011-04-07 | 2016-06-30 | Bayer Intellectual Property Gmbh | Imidazopyridazines as akt kinase inhibitors |
EP2802588B1 (en) * | 2012-01-10 | 2016-05-25 | Bayer Intellectual Property GmbH | Substituted pyrazolopyrimidines as akt kinase inhibitors |
ES2588186T3 (en) * | 2012-01-10 | 2016-10-31 | Bayer Intellectual Property Gmbh | Imidazopyrazines substituted as Akt kinase inhibitors |
MA38121A1 (en) * | 2012-11-30 | 2016-10-31 | Glaxosmithkline Llc | New pharmaceutical composition |
JP6835472B2 (en) | 2013-03-05 | 2021-02-24 | ユニバーシティ オブ テネシー リサーチ ファウンデーション | Compositions for the treatment of cancer |
US20150352121A1 (en) * | 2013-03-12 | 2015-12-10 | Glaxosmithkline Llc | Combination |
WO2014153001A1 (en) * | 2013-03-14 | 2014-09-25 | Epizyme, Inc. | Combination therapy for treating cancer |
CA2936024A1 (en) * | 2014-01-09 | 2015-07-16 | Bayer Pharma Aktiengesellschaft | Amido-substituted imidazopyridazines useful in the treatment of hyper-proliferative and/or angiogenesis disorders |
US10774086B2 (en) | 2016-11-28 | 2020-09-15 | Bristol-Myers Squibb Company | GSK-3 inhibitors |
EP3453706A1 (en) | 2017-09-08 | 2019-03-13 | Basf Se | Pesticidal imidazole compounds |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2002119574A (en) | 1999-12-23 | 2004-01-10 | Нитромед, Инк. (Us) | Nitrosated and nitrosylated cyclooxygenase-2 inhibitors, compositions based on them and methods for their use |
WO2001074815A2 (en) | 2000-03-31 | 2001-10-11 | Ortho Mcneil Pharmaceutical, Inc. | Phenyl-substituted imidazopyridines |
DK1277754T3 (en) | 2000-04-27 | 2005-11-14 | Astellas Pharma Inc | imidazopyridine |
EP1608628A2 (en) | 2003-03-17 | 2005-12-28 | Takeda San Diego, Inc. | Histone deacetylase inhibitors |
US7579355B2 (en) | 2003-04-24 | 2009-08-25 | Merck & Co., Inc. | Inhibitors of Akt activity |
ATE380816T1 (en) | 2003-07-30 | 2007-12-15 | S A L V A T Lab Sa | SUBSTITUTED IMIDAZOPYRIMIDINES FOR THE PREVENTION AND TREATMENT OF CANCER |
CN1942465A (en) | 2004-04-09 | 2007-04-04 | 默克公司 | Inhibitors of AKT activity |
EP1784175A4 (en) | 2004-08-23 | 2009-07-22 | Merck & Co Inc | Inhibitors of akt activity |
WO2006021303A1 (en) | 2004-08-24 | 2006-03-02 | Basf Aktiengesellschaft | Imidazolium-methyl sulfites for use as starting compounds for producing ionic liquids |
EP1827436A4 (en) | 2004-12-15 | 2011-08-10 | Merck Sharp & Dohme | Inhibitors of akt activity |
EP1902056A2 (en) | 2005-05-20 | 2008-03-26 | Array Biopharma, Inc. | Raf inhibitor compounds and methods of use thereof |
BRPI0611717A2 (en) | 2005-06-10 | 2009-01-13 | Merck & Co Inc | compound, pharmaceutical composition and use of the compound |
US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
PE20070978A1 (en) | 2006-02-14 | 2007-11-15 | Novartis Ag | HETEROCICLIC COMPOUNDS AS INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASES (PI3Ks) |
US7530313B2 (en) | 2006-05-12 | 2009-05-12 | Day & Zimmerman, Inc. | Self-destruct fuze delay mechanism |
AR064010A1 (en) | 2006-12-06 | 2009-03-04 | Merck & Co Inc | AKT ACTIVITY INHIBITORS |
JP5451602B2 (en) * | 2007-06-08 | 2014-03-26 | アッヴィ・インコーポレイテッド | 5-Heteroaryl-substituted indazoles as kinase inhibitors |
ES2396177T3 (en) | 2007-08-14 | 2013-02-19 | Bayer Intellectual Property Gmbh | Fused bicyclic pyrimidines |
EA201000297A1 (en) | 2007-08-14 | 2010-08-30 | Байер Шеринг Фарма Акциенгезельшафт | CONDENSED BICYCLIC IMIDAZOLES |
US20100331333A1 (en) | 2007-12-21 | 2010-12-30 | Wyeth Llc | Imidazo [1,2-B] Pyridazine Compounds |
JP2011522048A (en) | 2008-06-03 | 2011-07-28 | メルク・シャープ・エンド・ドーム・コーポレイション | Inhibitor of AKT activity |
MX2010013224A (en) | 2008-06-03 | 2010-12-21 | Merck Sharp & Dohme | Inhibitors of akt activity. |
AR074072A1 (en) | 2008-11-11 | 2010-12-22 | Lilly Co Eli | COMPOSITE OF IMIDAZOL -PIPERIDIN -PIRROL-PIRIMIDIN-6-ONA, PHARMACEUTICAL COMPOSITION THAT INCLUDES IT AND ITS USE TO PREPARE A USEFUL MEDICINAL PRODUCT TO TREAT MULTIFORM GLIOBLASTOMA |
PA8854101A1 (en) | 2008-12-18 | 2010-07-27 | Ortho Mcneil Janssen Pharm | IMIDAZOL BICYCLIC DERIVATIVES REPLACED AS MODULATORS OF GAMMA SECRETASA |
EP2391623A4 (en) | 2009-02-02 | 2012-09-05 | Merck Sharp & Dohme | Inhibitors of akt activity |
MX2011008583A (en) * | 2009-02-13 | 2011-12-12 | Bayer Pharma AG | Fused pyrimidines. |
EP2406250B1 (en) | 2009-03-11 | 2015-08-12 | Merck Sharp & Dohme Corp. | Inhibitors of akt activity |
US8691825B2 (en) * | 2009-04-01 | 2014-04-08 | Merck Sharp & Dohme Corp. | Inhibitors of AKT activity |
AR076936A1 (en) | 2009-06-02 | 2011-07-20 | Vitae Pharmaceuticals Inc | CARBAMATE AND UREA INHIBITORS OF THE 11 BETA HYDROXIESTEROID DEHYDROGENASE 1 |
US8546376B2 (en) | 2009-09-18 | 2013-10-01 | Almac Discovery Limited | Pharmaceutical compounds |
US8975265B2 (en) | 2010-07-12 | 2015-03-10 | Bayer Intellectual Property Gmbh | Substituted imidazo[1,2-a]pyrimidines and —pyridines |
WO2012013713A2 (en) * | 2010-07-28 | 2012-02-02 | Bayer Pharma Aktiengesellschaft | Substituted imidazo[1,2-b]pyridazines |
RS54480B1 (en) * | 2011-04-07 | 2016-06-30 | Bayer Intellectual Property Gmbh | Imidazopyridazines as akt kinase inhibitors |
-
2012
- 2012-04-05 RS RS20160005A patent/RS54480B1/en unknown
- 2012-04-05 SI SI201230430T patent/SI2694510T1/en unknown
- 2012-04-05 WO PCT/EP2012/056300 patent/WO2012136776A1/en active Application Filing
- 2012-04-05 AU AU2012238589A patent/AU2012238589B2/en not_active Ceased
- 2012-04-05 CU CUP2013000135A patent/CU24263B1/en unknown
- 2012-04-05 AP AP2013007215A patent/AP3597A/en active
- 2012-04-05 MX MX2013011699A patent/MX336865B/en active IP Right Grant
- 2012-04-05 ME MEP-2016-1A patent/ME02316B/en unknown
- 2012-04-05 JP JP2014503153A patent/JP5906303B2/en not_active Expired - Fee Related
- 2012-04-05 HU HUE12713963A patent/HUE026323T2/en unknown
- 2012-04-05 CN CN201280027994.5A patent/CN103596957B/en not_active Expired - Fee Related
- 2012-04-05 ES ES12713963.2T patent/ES2558780T3/en active Active
- 2012-04-05 CA CA2832374A patent/CA2832374A1/en not_active Abandoned
- 2012-04-05 PE PE2013002192A patent/PE20141380A1/en not_active Application Discontinuation
- 2012-04-05 SG SG2013072509A patent/SG193631A1/en unknown
- 2012-04-05 BR BR112013025777A patent/BR112013025777A2/en active Search and Examination
- 2012-04-05 EP EP12713963.2A patent/EP2694510B1/en active Active
- 2012-04-05 KR KR1020137029229A patent/KR20140022057A/en not_active Application Discontinuation
- 2012-04-05 DK DK12713963.2T patent/DK2694510T3/en active
- 2012-04-05 PT PT127139632T patent/PT2694510E/en unknown
- 2012-04-05 JO JOP/2012/0084A patent/JO3068B1/en active
- 2012-04-05 EA EA201301130A patent/EA024890B1/en not_active IP Right Cessation
- 2012-04-05 US US14/007,427 patent/US9206185B2/en not_active Expired - Fee Related
- 2012-04-05 MA MA36290A patent/MA35016B1/en unknown
- 2012-04-05 PL PL12713963T patent/PL2694510T3/en unknown
- 2012-04-06 TW TW101112356A patent/TWI535719B/en not_active IP Right Cessation
- 2012-04-09 UY UY0001034006A patent/UY34006A/en not_active Application Discontinuation
- 2012-04-09 AR ARP120101200A patent/AR087148A1/en active Pending
- 2012-05-04 UA UAA201312894A patent/UA111739C2/en unknown
-
2013
- 2013-09-26 ZA ZA2013/07223A patent/ZA201307223B/en unknown
- 2013-09-29 IL IL228567A patent/IL228567A0/en unknown
- 2013-10-03 TN TNP2013000400A patent/TN2013000400A1/en unknown
- 2013-10-07 CL CL2013002878A patent/CL2013002878A1/en unknown
- 2013-10-07 DO DO2013000226A patent/DOP2013000226A/en unknown
- 2013-10-07 GT GT201300238A patent/GT201300238A/en unknown
- 2013-10-07 CR CR20130515A patent/CR20130515A/en unknown
- 2013-10-07 CO CO13237923A patent/CO6862145A2/en active IP Right Grant
- 2013-10-07 NI NI201300105A patent/NI201300105A/en unknown
- 2013-11-04 EC ECSP13013008 patent/ECSP13013008A/en unknown
-
2015
- 2015-07-06 US US14/792,205 patent/US9604989B2/en not_active Expired - Fee Related
-
2016
- 2016-01-05 SM SM201600001T patent/SMT201600001B/en unknown
- 2016-01-05 HR HRP20160011TT patent/HRP20160011T1/en unknown
- 2016-01-08 CY CY20161100011T patent/CY1117163T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TN2013000400A1 (en) | Imidazopyridazines as akt kinase inhibitors | |
MX341456B (en) | Amino-quinolines as kinase inhibitors. | |
TN2014000138A1 (en) | Substituted benzylindazoles for use as bub1 kinase inhibitors in the treatment of hyperproliferative diseases. | |
MX355728B (en) | Kinase inhibitors. | |
MX2014001879A (en) | Amino quinazolines as kinase inhibitors. | |
MX339873B (en) | Serine/threonine kinase inhibitors. | |
GEP201706745B (en) | Forms of rifaximin and usage thereof | |
EP2566477A4 (en) | Amino-quinolines as kinase inhibitors | |
MX370649B (en) | Process for the preparation of teneligliptin. | |
PH12015500363A1 (en) | Prodrugs of amino quinazoline kinase inhibitor | |
NZ711192A (en) | Process for making benzoxazepin compounds | |
GEP201706626B (en) | Synthesis of (s)-nifuratel | |
HK1210616A1 (en) | Process for the preparation of c-fms kinase inhibitors c-fms | |
GB201107985D0 (en) | Process | |
NZ720805A (en) | Processes for the preparation of pyrimidinylcyclopentane compounds | |
AU2013314244A8 (en) | Novel inhibitor compounds of phosphodiesterase type 10A | |
AU2013347232A8 (en) | 3-Aminocyclopentane carboxamide derivatives | |
ZA201301799B (en) | Process for the preparation of pan-cdk inhibitors of the formula (i),and intermediates of the preparation | |
MX2012014796A (en) | Process for preparing 4-hydroxypyridines. | |
MX2014009084A (en) | Pyrimidooxazocine derivatives as mtor - inhibitors. | |
IN2014DN07191A (en) | ||
TN2013000128A1 (en) | Process for preparing pan-cdk inhibitors of the formula (1), and intermediates in the preparation | |
MY162973A (en) | New process for the synthesis of agomelatine | |
UA77456U (en) | Method for preventing gingivitis |